Experience of using the 1,5% Tetranyl U cream in patients with tinea corporis and tinea cruris

Abstract

BACKGROUND: Over the past ten years, there has been a persistent increase in the resistance of dermatophytes to antifungal drugs. The development of new drugs and the evaluation of the effectiveness of medicines is a priority in mycology.

AIMS: Evaluation of the effectiveness and safety of using the cream containing Tetranyl U and 10% urea in the treatment of tinea corporis and tinea cruris.

MATERIALS AND METHODS: The study included 30 patients with a laboratory-confirmed diagnosis of tinea corporis and tinea cruris of mild to moderate severity. Patients were recommended to use the cream which was applied to the lesions 2 times a day for 3 weeks. The evaluation of the severity the course of mycosis and the effectiveness of the cream was carried out by calculating a 4-point PGA (Physician Global Assessment) before treatment and after 3 weeks of using the cream.

RESULTS: According to the results of the study, the clinical efficacy was 81.8%. Mycological response (negative direct microscopy + mycological culture) was achieved in 82.8% of patients.

CONCLUSION: The cream containing Tetranyl U showed good efficacy and tolerability in the treatment of tinea corporis and tinea cruris, which is confirmed by the results of clinical and microbiological studies.

Keywords

dermatophytes / skin mycoses / tinea corporis / tinea cruris / Tetranyl U

References

[1] Tirado-Sánchez A, González GM, Bonifaz A. Endemic mycoses: epidemiology and diagnostic strategies. Expert Rev Anti Infect Ther. 2020;18(11):1105–1117. doi: 10.1080/14787210.2020.1792774

[2] Tirado-Sánchez A., González G.M., Bonifaz A. Endemic mycoses: epidemiology and diagnostic strategies // Expert Rev Anti Infect Ther. 2020. Vol. 18, N 11. Р. 1105–1117. doi: 10.1080/14787210.2020.1792774

[3] Sacheli R, Hayette MP. Antifungal resistance in dermatophytes: genetic considerations, clinical presentations and alternative therapies. J Fungi (Basel). 2021;7(11):983. doi: 10.3390/jof7110983

[4] Sacheli R., Hayette M.P. Antifungal resistance in dermatophytes: genetic considerations, clinical presentations and alternative therapies // J Fungi (Basel). 2021. Vol. 7, N 11. Р. 983. doi: 10.3390/jof7110983

[5] Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2–15. doi: 10.1111/j.1439-0507.2008.01606.x

[6] Havlickova B., Czaika V.A., Friedrich M. Epidemiological trends in skin mycoses worldwide // Mycoses. 2008. Vol. 51, Suppl 4. Р. 2–15. doi: 10.1111/j.1439-0507.2008.01606.x

[7] Resources and activities of medical organizations of dermatovenerological profile. The incidence of sexually transmitted infections, infectious skin diseases and skin diseases for 2017–2018. (Statistical materials). Moscow; 2019. 208 p. (In Russ).

[8] Ресурсы и деятельность медицинских организаций дерматовенерологического профиля. Заболеваемость инфекциями, передаваемыми половым путем, заразными кожными болезнями и болезнями кожи за 2017–2018 годы. (Статистические материалы). Москва, 2019. 208 с.

[9] Monod M. Antifungal resistance in dermatophytes: Emerging problem and challenge for the medical community. J Mycol Med. 2019;29(4):283–284. doi: 10.1016/j.mycmed.2019.100913

[10] Monod M. Antifungal resistance in dermatophytes: Emerging problem and challenge for the medical community // J Mycol Med. 2019. Vol. 29, N 4. Р. 283–284. doi: 10.1016/j.mycmed.2019.100913

[11] Nenoff P, Verma SB, Vasani R, et al. The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes ― a molecular study. Mycoses. 2019;62(4):336–356. doi: 10.1111/myc.12878

[12] Nenoff P., Verma S.B., Vasani R., et al. The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes ― a molecular study // Mycoses. 2019. Vol. 62, N 4. Р. 336–356. doi: 10.1111/myc.12878

[13] Shi D, Zhao Y, Yan H, et al. Antifungal effects of undecylenic acid on the biofilm formation of Candida albicans. Int J Clin Pharmacol Ther. 2016;54(5):343–353. doi: 10.5414/CP202460

[14] Shi D., Zhao Y., Yan H., et al. Antifungal effects of undecylenic acid on the biofilm formation of Candida albicans // Int J Clin Pharmacol Ther. 2016. Vol. 54, N 5. Р. 343–353. doi: 10.5414/CP202460

[15] Mionić Ebersold M, Petrović M, Fong WK, et al. Hexosomes with Undecylenic acid efficient against Candida albicans. Nanomaterials (Basel). 2018;8(2):91. doi: 10.3390/nano8020091

[16] Mionić Ebersold M., Petrović M., Fong W.K., et al. Hexosomes with Undecylenic acid efficient against Candida albicans // Nanomaterials (Basel). 2018. Vol. 8, N 2. Р. 91. doi: 10.3390/nano8020091

[17] Smith EB, Powell RP, Graham JL, Ulrich JA. Topical undecylenic acid in tinea pedis: a new look. Int J Dermatol. 1977;16(1):52–56. doi: 10.1111/j.1365-4362.1977.tb00741.x

[18] Smith E.B., Powell R.P., Graham J.L., Ulrich J.A. Topical undecylenic acid in tinea pedis: a new look // Int J Dermatol. 1977. Vol. 16, N 1. Р. 52–56. doi: 10.1111/j.1365-4362.1977.tb00741.x

[19] Karpova OA. Mycostop ― an integrated approach to the treatment and prevention of onychomycosis. Advances in Medical Mycology. 2019;20:136–140. (In Russ).

[20] Карпова О.А. Микостоп ― комплексный подход к лечению и профилактике онихомикоза // Успехи медицинской микологии. 2019. Т. 20. С. 136–140.

[21] Clinical recommendations of the Russian Society of Dermatovenerologists and Cosmetologists “Mycosis of the scalp, trunk, hands and feet”. Moscow; 2020. 53 р. (In Russ).

[22] Клинические рекомендации Российского общества дерматовенерологов и косметологов «Микозы кожи головы, туловища, кистей и стоп». Москва, 2020. 53 с.

RIGHTS & PERMISSIONS

Maximov I.S., Petukhova E.V.